People with a left ventricular assist device (LVAD) most commonly die from multi-organ failure (about 26%), hemorrhagic stroke (about 24%), or worsening heart failure (about 21%). Some deaths are acute emergencies, while others follow a gradual decline that eventually leads to a decision to deactivate the device. With the current-generation HeartMate 3 pump, survival at one year is roughly 88% and drops to about 58% at five years, meaning a significant number of patients will face end-of-life questions while still on the device.
Stroke: The Most Sudden Threat
Hemorrhagic stroke, where bleeding occurs inside the brain, is one of the deadliest complications for LVAD patients. In-hospital mortality for hemorrhagic stroke reaches nearly 89%, compared to about 21% for strokes caused by blood clots. The continuous-flow design of the pump requires patients to take blood thinners constantly, and when those medications push anticoagulation too high, the risk of a brain bleed rises. Concurrent infections also appear to play a role: infections were present in about 45% of hemorrhagic stroke cases in one study of centrifugal-flow devices.
Clot-based (ischemic) strokes happen more frequently overall but are more survivable. These can originate from clots forming inside the LVAD itself, debris in the outflow tubing, or clots traveling from the heart chambers. In nearly half of ischemic stroke cases, blood-thinner levels were too low at the time of the event. For both stroke types, severity at onset and kidney function at the time are strong predictors of whether the patient survives the following 30 days.
Right Heart Failure
An LVAD supports only the left side of the heart. Once the pump is running, it can pull blood through the lungs faster than the right ventricle can keep up. When the LVAD delivers more volume than the right side of the heart can handle, the right ventricle becomes chronically overloaded with pressure and fluid. Over time, this stretches the valve between the right chambers (the tricuspid valve), allowing blood to leak backward and worsening the overload in a self-reinforcing cycle.
The LVAD also shifts the wall between the two ventricles to the left, which further distorts right-side geometry and makes that backward leaking worse. Right heart failure is a major contributor to both the “heart failure” and “multi-organ failure” categories that together account for nearly half of all LVAD deaths. It leads to fluid buildup throughout the body, kidney and liver dysfunction, and eventually the inability of multiple organ systems to function.
Infection and Sepsis
Every LVAD has a driveline, a cable that exits through the skin to connect the internal pump to an external power source. That permanent opening in the skin creates a lifelong entry point for bacteria. Driveline infections are common, and while many can be managed with antibiotics and wound care, some progress to bloodstream infections and full-blown sepsis.
The risk grows over time. Roughly 8% of patients develop a bloodstream infection within six months of a driveline infection diagnosis, and that figure rises to 18% by twelve months. Sepsis has historically been responsible for a large share of LVAD deaths: 41% of deaths with older pulsatile devices and about 20% at six months with newer continuous-flow pumps. When a bloodstream infection is confirmed in an LVAD patient, it is considered serious enough that the patient is upgraded to the highest priority for an urgent heart transplant.
Gastrointestinal Bleeding
LVAD patients bleed from the gut far more often than the general population. The pump’s continuous flow reduces the normal pulse pressure in the arteries, mimicking the conditions seen in severe aortic valve narrowing. That change in blood flow dynamics triggers the growth of fragile, abnormal blood vessels in the stomach and intestines (a condition sometimes called Heyde’s syndrome). These vessels rupture easily, especially because the patient is on blood thinners.
GI bleeding doesn’t usually kill directly with a single episode, but it significantly raises the risk of death over time. After adjusting for age, diabetes, and heart failure severity, patients who experience GI bleeding have more than double the mortality risk compared to LVAD patients who don’t. Repeated bleeding episodes also force difficult decisions about reducing blood-thinner doses, which then raises the risk of pump clots and stroke.
Pump Thrombosis
Blood clots can form inside the pump itself, partially or fully blocking its rotor. This was a serious problem with earlier LVAD generations: roughly 7 to 11% of patients with older devices needed the pump surgically replaced within two years because of clotting. The current HeartMate 3, which uses a magnetically levitated rotor with a built-in artificial pulse to wash out stagnant blood, has dramatically reduced this risk to about 1.1% at two years. Pump thrombosis hasn’t disappeared, but it is far less likely to be the cause of death with modern devices.
What Happens During LVAD Deactivation
Many LVAD patients don’t die from a sudden emergency. Instead, they develop a progressive illness, whether worsening organ failure, advanced cancer, or another terminal condition, that reaches a point where continued LVAD support only prolongs dying. At that stage, patients or their families may choose to turn off the device.
Deactivation is legally and ethically treated as withdrawal of life-sustaining technology, the same category as removing a ventilator. It is not considered physician-assisted suicide. The process requires coordination among heart failure specialists, palliative care teams, and the patient’s family. It is typically planned in advance, with clear protocols and checklists.
Once the LVAD is turned off, cardiac output drops immediately and dramatically. The heart that needed the pump in the first place cannot maintain circulation on its own. Death typically follows within minutes to hours, not days. Because the decline is so rapid, patients receive higher-than-usual doses of comfort medications before deactivation to prevent shortness of breath and anxiety. Intranasal pain relievers and sedatives allow the process to happen quickly and without distress. In documented cases, patients have died comfortably after this approach.
How Families Experience the Process
For families, the LVAD adds a layer of complexity that other end-of-life situations don’t have. The device is keeping the person alive in a very mechanical, visible way. There is a controller, batteries, and an audible alarm system. Deciding to deactivate can feel different from agreeing to stop a medication or remove a breathing tube, even though ethically and legally it is the same decision.
If the patient is conscious and able to participate, they make the decision themselves. More often, by the time deactivation is discussed, the patient is too ill, and the family or designated decision-maker is involved. Palliative care teams typically guide families through what to expect: that the process is fast, that comfort medications will be given first, and that the person will not gasp or struggle if properly medicated. Some families choose to have the device turned off at home with hospice support, though in-hospital deactivation is more common because of the medical coordination involved.